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WS3.1 Gastric aspiration into the CF lung − relationship with reﬂux
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Objectives: Gastro-oesophageal reﬂux (GOR) is the retrograde movement of gastric
contents up the oesophagus. This results in both classical and atypical symptoms.
GOR is common in CF affecting 35−81% of patients and it may be associated
with deteriorating lung function. We investigated microaspiration into the CF lung,
characterised symptoms of reﬂux and compared these parameters with lung function.
Methods: FEV1 % predicted was recorded in 37 CF patients (19 male), mean age
29 (range 17−60) years. GOR symptom severity was assessed using the DeMeester
Reﬂux score (0−9; <1 normal) and extra oesophageal reﬂux (EOR) using the Reﬂux
Symptom Index (RSI) score (0−45; <13 normal). Pepsin (ELISA) and total bile acids
(TBA) (mass spectrometry) were measured in the sputum of 29 and 24 CF patients
respectively.
Results: Pepsin was identiﬁed in 17 of 29 (59%) (median 111 ng/ml) and TBA in 23
of 24 (96%) (median 0.18mMol/L) patients. RSI scores showed atypical symptoms in
87% of patients, whereas, classical symptoms (DeMeester scores) were identiﬁed in
43% of patients. 88% pepsin-positive and 87% TBA-positive patients suffered EOR
symptoms, however 53% pepsin-positive and 61% TBA-positive patients experienced
GOR symptoms. FEV1 ranged from 12% to 101% of predicted (median 43%) but was
not correlated with biomarkers or symptoms of reﬂux.
Conclusion: Gastric and biliary reﬂux into the lungs are very common in CF patients.
EOR symptoms may be more closely associated with CF than GOR. Microaspiration
of gastric content into the lung was not correlated with FEV1 and occurred across the
spectrum of disease severity.
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Objectives: Intestinal inﬂammation is a common complication of cystic ﬁbrosis
(CF). Small intestinal bacterial overgrowth (SIBO) has been discussed as prevalent
determinant of intestinal inﬂammation in CF patients before lung transplantation
(LuTx). Data on intestinal inﬂammation in post-transplant setting are scarce. Aim
of this ongoing prospective study is to evaluate intestinal inﬂammation and its
underlying mechanisms in CF patients after LuTx.
Methods: So far, 13 CF patients with LuTx (all with pancreatic insufﬁciency,
median age 33 y, range 23−57 y; 43% male) attending our outpatient clinic were
tested for intestinal inﬂammation by measuring of calprotectin in stool and IgG
and IgA ASCA in serum. Intestinal infection was excluded by stool cultures, celiac
disease by negative EMA/TTG antibodies. In 9 of 13 patients glucose-H2 breath
test was performed to diagnose SIBO.
Results: Calprotectin was increased in all 13 patients (median 182mg/kg, range 69–
444mg/kg). 12 of 13 (92%) patients were positive for either IgG (7 of 13, 54%) or
IgA (9 of 13, 69%) ASCA. In 4 of 9 patients (44%) SIBO was diagnosed. Patients
with SIBO had markedly increased fecal calprotectin levels (median 186mg/kg,
range 155–444mg/kg) compared with patients without SIBO (median 135mg/kg,
range 69–146mg/kg) (p< 0.01).
Conclusion: Intestinal inﬂammation was observed in all studied CF patients
after LuTx as measured by increased fecal calprotectin and serum ASCA im-
munoglobulin levels. Patients with SIBO had noticeably increased fecal calprotectin
levels, underlining SIBO as one of the crucial pathogenetic factors in intestinal
inﬂammation in CF patients in post-transplant setting.
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Objectives: An early site of Cystic Fibrosis (CF) manifestation is the intestinal dis-
trict. Clinical evidence indicates a role for intestinal microbiota in extra-pulmonary
CF manifestations, along with impairment of patients’ life quality. Gut microbiota
seems to be involved in both human co-metabolism and toxicity/efﬁcacy of drugs:
a reported higher bacterial load in CF patients’ gut could affect the quality of
life. To describe through molecular techniques the fecal dominant microbiota and
fecal/urinary metabolites in CF patients and controls.
Methods: Two patients’ cohorts were engaged: 36 CF and 16 controls. Temporal
Temperature Gel Electrophoresis (TTGE) was employed to have a ‘snapshot’
of predominant microbial community in fecal samples, and Solid Phase Micro
Extraction-Gas Chromatography/Mass Spectrometry (SPME-GC/MS) was used to
characterize fecal/urinary metabolites.
Conclusion: A separation between the two cohorts was found by means of
TTGE (c2 = 6.107, P = 0.0135) and fecal/urinary metabolites proﬁles (c2 = 11.827,
P= 0.0006). The multivariate analysis gave a model predictability of 95.5% for
TTGE proﬁles, and 91.0% for SPME-GC/MS ones. We found a prevalence of
Escherichia coli in CF and Eubacterium limosum in controls, reﬂecting an existing
dysbiotic status in CF intestine. We also found peculiar toxic compounds such as
cadaverine and putrescine in CF patients. Our results showed a predominant fecal
microbiota associated with CF status, along with a peculiar CF fecal metabolite
proﬁle. These results could have a pitfall in diagnosis and CF patients’ care.
WS3.4 Clostridium difﬁcile, but not Giardia lamblia, is a frequent
ﬁnding in the stool of CF-patients
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Objectives: Giardia and Clostridium difﬁcile have been reported in up to 28%,
respectively 50% of Cystic ﬁbrosis (CF)-patients. Most of these patients remain
asymptomatic, but villous atrophy with severe malabsorption (giardiasis) and severe,
life-threatening Clostridium difﬁcile enterocolitis has been rarely reported.
Methods: Clostridium difﬁcile (C. diff.) and toxin A/B (C. diff. Check® [Alere,
Ko¨ln, Germany]) and Giardia lamblia (Giardia II® [Alere, Ko¨ln, Germany])
were investigated in a single stool probe of 45 CF-patients >4 years of age
(15.4±8.0 years old), 25 IBD-patients (21.2±1.8 years old) and 22 healthy relatives
of CF-patients (controls) (21.4±13.2 years old). Exclusion criteria was an acute
gastrointestinal or respiratory exacerbation 4 weeks prior to investigation.
Results: Giardia was detected in 9% of CF-patients and 0% of IBD-patients
and controls (ns). Giardia-positive patients were signiﬁcantly older than negative
(25.4±10.8 versus 14.4±7.0; p = 0.007) and all were over 20 years of age (preva-
lence in this age group 28%). Clostridium difﬁcile was detected in 76% of CF-
patients, 20% of IBD-patients and 5% of controls (p< 0.001). Clostridium difﬁcile
toxin was found in 9% of CF-patients compared to 4% of IBD patients and 5%
of controls (ns). All positive patients were asymptomatic. There was no signiﬁcant
difference with regard to BMI or antibiotic treatment.
Conclusion: Giardia lamblia is highly prevalent in CF-adults with 28%, but less
frequent than reported. Clostridium difﬁcile, but not toxin A/B, are regular ﬁndings
(76%) independent of age and antibiotic therapy.
